Efficacy and Safety of Infliximab for Ankylosing Spondylitis in Japanese Patients: A Retrospective Study of 11 Cases

Yusuke Kubo; Masanobu Ohishi; Yasuharu Nakashima; Ken Okazaki; Jun-Ichi Fukushi; Akiko Oyamada; Yukihide Iwamoto

Efficacy and Safety of Infliximab for Ankylosing Spondylitis in Japanese Patients: A Retrospective Study of 11 Cases

Yusuke Kubo
, Masanobu Ohishi
, Yasuharu Nakashima
, Ken Okazaki
, Jun-Ichi Fukushi
, Akiko Oyamada
, Yukihide Iwamoto

研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

抄録

PURPOSE: Tumor necrosis factor inhibitors (TNFi) such as infliximab (IFX) and adalimumab have been shown to be efficacious not only for rheumatoid arthritis but also for Ankylosing Spondylitis (AS). However, only a limited number of reports regarding the effect of TNFi on AS in Japanese population have been published.

MATERIALS AND METHODS: We retrospectively evaluated all 11 patients (8 males and 3 females) with AS who were treated with IFX.

RESULTS: After a mean follow-up period of 19 months, the mean BASDAI decreased from 4.7 ± 2.2 to 1.7 ± 1.2 and the serum CRP level decreased from 1.62 ± 1.94 mg/dl to 0.23 ± 0.45 mg/dl. There was no case of serious infection or anaphylaxis.

CONCLUSIONS: Our results indicate that IFX is efficacious and safe for AS in Japanese patients.

本文言語	英語
ページ（範囲）	316-322
ページ数	7
ジャーナル	Fukuoka igaku zasshi = Hukuoka acta medica
巻	106
号	12
出版ステータス	出版済み - 12月 1 2015

!!!All Science Journal Classification (ASJC) codes

医学一般

他のファイルとリンク

引用スタイル

@article{06fa6989f4b04f92ac0642f26e771638,

title = "Efficacy and Safety of Infliximab for Ankylosing Spondylitis in Japanese Patients: A Retrospective Study of 11 Cases",

abstract = "PURPOSE: Tumor necrosis factor inhibitors (TNFi) such as infliximab (IFX) and adalimumab have been shown to be efficacious not only for rheumatoid arthritis but also for Ankylosing Spondylitis (AS). However, only a limited number of reports regarding the effect of TNFi on AS in Japanese population have been published.MATERIALS AND METHODS: We retrospectively evaluated all 11 patients (8 males and 3 females) with AS who were treated with IFX.RESULTS: After a mean follow-up period of 19 months, the mean BASDAI decreased from 4.7 ± 2.2 to 1.7 ± 1.2 and the serum CRP level decreased from 1.62 ± 1.94 mg/dl to 0.23 ± 0.45 mg/dl. There was no case of serious infection or anaphylaxis.CONCLUSIONS: Our results indicate that IFX is efficacious and safe for AS in Japanese patients.",

author = "Yusuke Kubo and Masanobu Ohishi and Yasuharu Nakashima and Ken Okazaki and Jun-Ichi Fukushi and Akiko Oyamada and Yukihide Iwamoto",

year = "2015",

month = dec,

day = "1",

language = "English",

volume = "106",

pages = "316--322",

journal = "Fukuoka igaku zasshi = Hukuoka acta medica",

issn = "0016-254X",

publisher = "Fukuoka Medical Society/Fukuoka Igakkai",

number = "12",

}

TY - JOUR

T1 - Efficacy and Safety of Infliximab for Ankylosing Spondylitis in Japanese Patients

T2 - A Retrospective Study of 11 Cases

AU - Kubo, Yusuke

AU - Ohishi, Masanobu

AU - Nakashima, Yasuharu

AU - Okazaki, Ken

AU - Fukushi, Jun-Ichi

AU - Oyamada, Akiko

AU - Iwamoto, Yukihide

PY - 2015/12/1

Y1 - 2015/12/1

N2 - PURPOSE: Tumor necrosis factor inhibitors (TNFi) such as infliximab (IFX) and adalimumab have been shown to be efficacious not only for rheumatoid arthritis but also for Ankylosing Spondylitis (AS). However, only a limited number of reports regarding the effect of TNFi on AS in Japanese population have been published.MATERIALS AND METHODS: We retrospectively evaluated all 11 patients (8 males and 3 females) with AS who were treated with IFX.RESULTS: After a mean follow-up period of 19 months, the mean BASDAI decreased from 4.7 ± 2.2 to 1.7 ± 1.2 and the serum CRP level decreased from 1.62 ± 1.94 mg/dl to 0.23 ± 0.45 mg/dl. There was no case of serious infection or anaphylaxis.CONCLUSIONS: Our results indicate that IFX is efficacious and safe for AS in Japanese patients.

AB - PURPOSE: Tumor necrosis factor inhibitors (TNFi) such as infliximab (IFX) and adalimumab have been shown to be efficacious not only for rheumatoid arthritis but also for Ankylosing Spondylitis (AS). However, only a limited number of reports regarding the effect of TNFi on AS in Japanese population have been published.MATERIALS AND METHODS: We retrospectively evaluated all 11 patients (8 males and 3 females) with AS who were treated with IFX.RESULTS: After a mean follow-up period of 19 months, the mean BASDAI decreased from 4.7 ± 2.2 to 1.7 ± 1.2 and the serum CRP level decreased from 1.62 ± 1.94 mg/dl to 0.23 ± 0.45 mg/dl. There was no case of serious infection or anaphylaxis.CONCLUSIONS: Our results indicate that IFX is efficacious and safe for AS in Japanese patients.

UR - https://www.scopus.com/pages/publications/84982797700

UR - https://www.scopus.com/pages/publications/84982797700#tab=citedBy

M3 - Article

C2 - 27159947

AN - SCOPUS:84982797700

SN - 0016-254X

VL - 106

SP - 316

EP - 322

JO - Fukuoka igaku zasshi = Hukuoka acta medica

JF - Fukuoka igaku zasshi = Hukuoka acta medica

IS - 12

ER -

Efficacy and Safety of Infliximab for Ankylosing Spondylitis in Japanese Patients: A Retrospective Study of 11 Cases

抄録

!!!All Science Journal Classification (ASJC) codes

他のファイルとリンク

フィンガープリント

引用スタイル